Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 13/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.59 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efinaconazole SCHEMBL8376515 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL300738 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL18289601 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL29858056 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL20259496 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL8375862 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Efinaconazole SCHEMBL20017139 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375955 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375839 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| SCHEMBL8375117 | 0.94 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628668-B1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMA CO LTD (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-10829475-B2 | Production and purification methods for efinaconazole | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-11-10 | — | — | US | disclosed |
| US-20200181110-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMA CO LTD (JP) | 2020-06-11 | — | — | US | disclosed |
| US-20190292166-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-06-14 | — | — | US | disclosed |
| WO-2016193917-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162833-A1 | PROCESS FOR THE PREPARATION OF EFINACONAZOLE | CYP3A43, CYP3A5, CYP51A1 | CYP3A4 4/4885CYP2C9 13/4885CYP2C19 12/4885 |
| US-20190292166-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
| US-20200181110-A1 | PRODUCTION AND PURIFICATION METHODS FOR EFINACONAZOLE | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
| US-10829475-B2 | Production and purification methods for efinaconazole | CYP4B1, ERG28, CYP4F3 | CYP3A4 6/4885CYP2C9 50/4885CYP2C19 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.